Catalent, Inc. to Post Q1 2023 Earnings of $0.70 Per Share, William Blair Forecasts (NYSE:CTLT)

Catalent, Inc. (NYSE:CTLTGet Rating) – Research analysts at William Blair issued their Q1 2023 earnings per share (EPS) estimates for shares of Catalent in a report released on Tuesday, August 30th. William Blair analyst J. Kreger forecasts that the company will post earnings per share of $0.70 for the quarter. The consensus estimate for Catalent’s current full-year earnings is $3.95 per share. William Blair also issued estimates for Catalent’s Q2 2023 earnings at $0.87 EPS, Q3 2023 earnings at $0.99 EPS and Q4 2023 earnings at $1.15 EPS.

Catalent (NYSE:CTLTGet Rating) last announced its earnings results on Monday, August 29th. The company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.15 by $0.04. Catalent had a return on equity of 14.83% and a net margin of 10.56%. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period in the previous year, the business earned $1.08 EPS. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis.

Other analysts have also recently issued research reports about the company. Jefferies Financial Group lowered their price target on Catalent from $130.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday. Royal Bank of Canada lowered their price target on Catalent from $155.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday. Barclays lowered their price target on Catalent from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Tuesday. Morgan Stanley lowered their price target on Catalent from $132.00 to $120.00 and set an “overweight” rating for the company in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Catalent from $110.00 to $105.00 and set a “hold” rating for the company in a research report on Tuesday. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $118.86.

Catalent Stock Down 0.9 %

Shares of CTLT stock opened at $87.58 on Thursday. Catalent has a 1-year low of $86.11 and a 1-year high of $142.64. The stock’s fifty day moving average price is $106.47 and its 200 day moving average price is $103.26. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.89 and a quick ratio of 2.25. The company has a market cap of $15.76 billion, a price-to-earnings ratio of 30.95, a price-to-earnings-growth ratio of 1.42 and a beta of 1.28.

Insider Activity

In related news, CEO Alessandro Maselli sold 816 shares of Catalent stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total value of $87,230.40. Following the completion of the transaction, the chief executive officer now owns 25,083 shares in the company, valued at approximately $2,681,372.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Alessandro Maselli sold 816 shares of Catalent stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total value of $87,230.40. Following the completion of the transaction, the chief executive officer now owns 25,083 shares in the company, valued at approximately $2,681,372.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Kay A. Schmidt sold 323 shares of Catalent stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total value of $34,528.70. Following the completion of the transaction, the senior vice president now owns 13,455 shares of the company’s stock, valued at approximately $1,438,339.50. The disclosure for this sale can be found here. Insiders sold a total of 18,136 shares of company stock valued at $1,885,920 in the last quarter. 0.53% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Catalent

Several large investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its stake in Catalent by 9.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 22,303,561 shares of the company’s stock worth $2,392,949,000 after buying an additional 2,011,520 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Catalent by 2.7% in the first quarter. Vanguard Group Inc. now owns 18,971,342 shares of the company’s stock valued at $2,103,921,000 after purchasing an additional 492,071 shares in the last quarter. BlackRock Inc. grew its position in shares of Catalent by 4.2% in the first quarter. BlackRock Inc. now owns 15,631,020 shares of the company’s stock valued at $1,733,479,000 after purchasing an additional 632,934 shares in the last quarter. State Street Corp grew its position in shares of Catalent by 3.8% in the first quarter. State Street Corp now owns 7,126,429 shares of the company’s stock valued at $790,321,000 after purchasing an additional 261,686 shares in the last quarter. Finally, Veritas Asset Management LLP grew its position in shares of Catalent by 15.3% in the first quarter. Veritas Asset Management LLP now owns 6,999,686 shares of the company’s stock valued at $776,265,000 after purchasing an additional 929,400 shares in the last quarter. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Catalent Company Profile

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.

Featured Articles

Earnings History and Estimates for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.